で公開中です! 詳しく見る
ACOR

Acorda Therapeutics

上場廃止済み

ACORは2024年4月11日に上場廃止となりました。

 

概要: Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.

従業員数: 102

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%
ニュートラル
Business Wire
2 年前
Acorda Therapeutics Announces Nasdaq Delisting Notification
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.
Acorda Therapeutics Announces Nasdaq Delisting Notification
ネガティブ
InvestorPlace
2 年前
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
Acorda Therapeutics (NASDAQ: ACOR ) stock is falling hard on Tuesday after the biopharmaceutical company signed a stalking horse asset purchase agreement with Merz Therapeutics. This agreement will have Merz Therapeutics acquire substantially all of the company's assets for $185 million.
ネガティブ
Market Watch
2 年前
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
ニュートラル
Business Wire
2 年前
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
ニュートラル
Business Wire
2 年前
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024.
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
ニュートラル
Business Wire
2 年前
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024.
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
ニュートラル
Business Wire
2 年前
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
価格チャートは Lightweight Charts™ を使用して実装されています